Aduhelm Pricing Considerations

Aduhelm Pricing Considerations

On June 7th 2021, the FDA made a landmark decision in clearing Aduhelm under the accelerated approval pathway for Alzheimer’s disease. As the first therapy approved in the category in nearly two decades, Aduhelm provides an option for patients with this highly debilitating disease; however, the price has resulted in significant concern around drug pricing and the potential impact to various stakeholders. Jupiter has outlined potential considerations and implications of Aduhelm’s pricing strategy.

DOWNLOAD PDF